Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
February 08 2022 - 4:05PM
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that it will host a conference call and webcast
on Wednesday, February 16, 2022 at 5:00 p.m. EST to
provide an update on the Company’s clinical programs, manufacturing
processes and pipeline.
The webcast will be accessible in the Investors
section of the Company's website at www.markertherapeutics.com.
Individuals can participate in the conference call by dialing
877-869-3847 (domestic) or 201-689-8261 (international) and
referring to the "Marker Therapeutics Clinical Program Update
Call."
The archived webcast will be available for replay
on the Marker website following the event.
About Marker Therapeutics,
Inc.Marker Therapeutics, Inc. is a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications. Marker’s
cell therapy technology is based on the selective expansion of
non-engineered, tumor-specific T cells that recognize tumor
associated antigens (i.e. tumor targets) and kill tumor cells
expressing those targets. This population of T cells is designed to
attack multiple tumor targets following infusion into patients and
to activate the patient’s immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cell therapies, we believe that our product candidates will
be easier and less expensive to manufacture, with reduced
toxicities, compared to current engineered CAR-T and TCR-based
approaches, and may provide patients with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling product profile, as compared to current
gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts.
IR and Media Contacts
Marker Therapeutics:
Neda SafarzadehVice President/Head of Investor
Relations, PR & Marketing(713)
400-6451investor.relations@markertherapeutics.com
Solebury Trout:
InvestorsXuan
Yangxyang@soleburytrout.com
MediaAmy
Bonannoabonanno@soleburytrout.com
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024